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INTRODUCTION
The treatment of allergic rhinitis (AR) includes avoidance, phar-
macologic treatment and immunotherapy. Contrary to other treat-
ment modalities, immunotherapy is the only therapeutic option
that modifies the basic allergic mechanism by inducing desensi-
tization and an anergy state for the allergen. Immunotherapy by
subcutaneous allergen injection (subcutaneous immunotherapy,
SCIT) has been used since Noon’s first report in 1911 and it has
been demonstrated to be a clinically effective treatment for aller-
gic disorders such as rhinoconjunctivitis or asthma. However, due
to the inconvenience, invasiveness and severe systemic adverse
effects of SCIT, other methods of administering allergen have
been developed such as the oral, sublingual, nasal or bronchial
routes (1, 2). Among them, the sublingual route is now widely
used to replace the subcutaneous route and it was acknowledged
by the WHO Allergic Rhinitis and Its Impact on Asthma (ARIA)
group that sublingual immunotherapy (SLIT) could be effective for
pollen or mite AR (3). However, there have been no studies on
Asian patients sensitized to Dermatophagoides pteronyssinus (Dp)
and Dermatophagoides farina (Df).
SLIT has recently been introduced and it is available for treat-
ing AR in Korea. This study was conducted to investigate the
short-term efficacy, the adverse effects and the patient satisfac-
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Original Articletion with SLIT for Korean patients with AR that is caused by
house dust mites.
MATERIALS AND METHODS
Patient selection
The patients who were diagnosed with AR at Seoul National
University Hospital or Seoul National University Bundang Ho-
spital and who were sensitized to Dp and Df were indicated for
SLIT. The patients who started to receive SLIT between Novem-
ber 2007 and July 2008 were included in this study. The patients
who had a history of asthma, atopic dermatitis or bronchial hyper-
responsiveness, but who didn’t need regular medication were
enrolled, while the patients with symptomatic asthma, atopic
dermatitis or bronchial hyper-responsiveness that required reg-
ular medication such as oral steroid, steroid inhaler or anti-hist-
amine were excluded. The subjects who suffered from immuno-
logic or hematologic disorder were also excluded. Sensitization
to Dp and Df was defined as 1) a serum specific IgE level for
Dp and Df ≥0.7 UI/mL on multiple allergen simultaneous tests
(MAST) or 2) the wheal diameters for Dp and Df were equal to
or greater than that of the positive control (histamine) on skin
prick tests. The Institutional Review Board of the Clinical Rese-
arch Institute at Seoul National University Hospital approved
the study protocol (H-0811-034-262).
Immunotherapy
Standardized extract of house dust mites (50% Dp/50% Df,
Pangramin
� SLIT, ALK-Abello, Madrid, Spain) was used for
the immunotherapy. During a 4-week up-dosing phase, the par-
ticipants took daily increasing doses from 1 to 5 drops of 1.6
STU/mL solution from day 1 to 10, 1 to 5 drops of 8 STU/mL
solution from day 11 to day 15, 1 to 5 drops of 40 STU/mL solu-
tion from day 16 to day 20, 1 to 5 drops of 200 STU/mL solu-
tion from day 21 to day 25 and 1 to 5 drops of 1,000 STU/mL
solution from day 26 to day 30. After reaching the maintenance
dose (5 drops of 1,000 STU/mL solution), the participants took
the allergen 3 times a week during the maintenance phase. The
patients had to keep the drops of allergen under their tongue for
2-3 min before swallowing. When the symptoms of AR were ag-
gravated during immunotherapy, the patients were allowed to
use antihistamine and/or intranasal steroid. 
Symptom score and satisfaction
All the patients were asked to complete the questionnaires before
SLIT and 6 months after receiving SLIT without medication. The
questionnaire included items on rhinorrhea, sneezing, nasal ob-
struction, itchy nose, olfactory disturbance, eye discomfort and
sleep discomfort. Each symptom was graded from 0 to 5 (0=no
symptom, 1=very mild symptom, 2=mild, 3=moderate, 4=severe,
5=very severe). The total nasal symptom score (TNSS) was de-
fined as the sum of the scores of five nasal symptoms, to, rhin-
orrhea, sneezing, nasal obstruction, itchy nose and olfactory
disturbance. The patients were also asked to assess their use of
anti-allergic medications such as anti-histamine, anti- leukot-
riene, and intranasal steroid according to 3 categories of, ‘‘increas-
ed’’, ‘‘similar’’, and ‘‘decreased’’, comparing months after SLIT
to before SLIT. Patient satisfaction was evaluated by 3 caterories
of ‘‘satisfied’’, ‘‘fair’’, and ‘‘unsatisfied’’ simultaneously with the
symptom evaluation after SLIT. If the participants had discon-
tinued SLIT, the reason of cessation was ascertained by telephone
interview. 
Adverse effects
To evaluate the adverse effects, the participants recorded the
adverse effects related to SLIT everyday on diary cards during
the whole period. 
Statistical analysis
The symptoms before and after SLIT were statistically analyzed
by paired t-tests. Student’s t-test, paired t-tests and the Wilcoxon
signed rank test were used to compare the symptomatic changes.
SPSS ver. 12.0 was used for all the statistical analysis. All of the
tests were 2-tailed and the criterion for statistical significance was
set at P<0.05.
RESULTS
One hundred forty-two patients (mean age, 16.3 yr; range, 5 to
71 yr) were enrolled in this study. Ninety-one of the patients were
male and 51 were female. Ninety-eight of 142 patients contin-
ued SLIT and 44 discontinued. Ninety-two of the 98 patients
who continued SLIT were considered in this study and the other
six were excluded due to the lack of data. The mean age of the
92 patients under consideration was 15.8 yr (range, 5 to 53 yr)
and the duration of allergic rhinits was a mean of 7.0 yr (range,
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Fig. 1. Changes of the symptom scores for all the patients who re-
ceived sublingual immunotherapy (SLIT). All the symptoms were
improved after SLIT with statistical significance (P<0.05 by paired t-
tests).
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0.511 to 30 yr). The mean duration of receiving SLIT was 9.8 months
(range, 6 to 13 months). All the symptoms, including the nasal
symptoms, the eye discomfort and the sleep disturbance, were
significantly improved after SLIT (Fig. 1). For the questionnaire
about the use of anti-allergic medication, 63 patients responded
‘‘decreased use’’, 24 patients responded ‘‘similar use’’, and 6 pa-
tients responded ‘‘decreased use’’.
When the patient satisfaction was assessed, forty-two patients
(45.7%) answered as ‘‘satisfied’’, 39 patients (42.4%) answered
as ‘‘fairly satisfied’’ and 11 patients (12%) answered as ‘‘unsat-
isfied’’. When the TNSS was compared before and after SLIT
according to the satisfaction, respectively, the patients who were
‘‘satisfied’’ or ‘‘fairly satisfied’’ had significant improvement of
their TNSS. However, the TNSS was not significantly changed
for the unsatisfied patients (Fig. 2). When comparing symptoms
between the patients who were ‘‘satisfied’’ and ‘‘fairly satisfied’’,
the latter had more severe symptoms before and after SLIT. How-
ever, the degree of changes of the TNSS was not different for
each group (Fig. 3).
The incidence of adverse effects of SLIT was 52.1% (48 of
92 patients) during first 30 days, which is the up-dosing phase.
Aggravation of the AR symptoms was the most common adverse
effect during the up-dosing phase (Table 1). After 6 months or
more, 13 patients (14.1%) had experienced temporary adverse
effects (Table 1). However, these adverse effects, including wheez-
ing and breathing discomfort, were temporary and they subsided
spontaneously without medication. None of the patients need-
ed to visit an emergency room due to adverse effects. 
Forty-four patients (30.1%) with mean age of 17.3 yr (range,
5 to 71 yr) discontinued SLIT. The male to female ratio was 26:
18. Among these patients, 36 patients responded to our telephone
interview. Twenty-one of 36 patients ceased SLIT after 3 months
and 8 patients ceased SLIT after 4-6 months and 7 patients ceased
SLIT after 7 months. The reasons for discontinuation of SLIT
were inability to take medication according to schedule (n=10,
27.8%), ineffectiveness (n=8, 22.2%), the discomfort of regular-
ly visiting the hospital regularly (n=6, 16.7%) and adverse effects
(n=5, 13.9%). The adverse effects causing discontinuance includ-
ed aggravation of the symptoms of AR (n=2), fever (n=1), gas-
trointestinal trouble (n=1) and skin rash (n=1). High cost (n=2),
the problem of storing the allergen (n=1) and pregnancy (n=1)
were also reported. Three patients answered that they thought
SLIT was not useful any more due to the improvement of symp-
toms.
DISCUSSION
Clinical trials for evaluating the safety and efficacy of SLIT were
initiated in 1980s and in 2001, and the WHO ARIA group report-
ed that SLIT could be effective for treating AR (3). A meta analy-
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Fig. 2. Comparing the total nasal symptom scores (TNSSs) before
and after sublingual immunotherapy (SLIT) in the satisfied, the fairly
satisfied and the unsatisfied groups. The satisfied and the fairly sat-
isfied group got better, with statistical significance. However, the NTSS
of the unsatisfied group was not improved after SLIT. 
*statistical analysis using paired t-tests; 
� statistical analysis using the
Wilcoxon signed rank test.
Fig. 3. Comparing the total nasal symptom scores (TNSSs) of the sat-
isfied group with those of the fairly satisfied group. The fairly satisfied
group had higher NTSSs before and after sublingual immunothera-
py than the satisfied group. However, the change of the TNSS in the
satisfied group didn’t differ from that in the fairly satisfied group.
*P<0.05 (Student’s t-test).
Adverse effects Up-dosing phase ≥6 months
Table 1. Adverse effects of sublingual immunotherapy 
Aggravation of symptoms 31 (33.7%) 7 (7.6%)
Itching sense of the oral cavity or insert the lip 9 (9.8%) 1 (1.1%)
Itching sense or discomfort of the eye 23 (25.0%) 3 (3.3%)
Skin itching or rash 15 (16.3%) 3 (3.3%)
Gastrointestinal trouble 14 (15.2%) 1 (1.1%)
Breathing discomfort 2 (2.2%) 5 (5.4%)
Wheezing 2 (2.2%) 0
The numbers are not mutually exclusive.sis involving 21 trials and 959 SLIT subjects indicated that SLIT
had efficacy against allergic symptoms (4). As the evidence has
accumulated, SLIT has received much attention as a valid treat-
ment for AR around the world. 
This study revealed that all the symptoms were changed for
the better after SLIT in patients with house dust mites AR under-
went SLIT. It was not easy to say that house dust mites SLIT had
efficacy against AR in our series because the duration of the fol-
low-up was short and our study was not a double-blind, placebo
controlled trial. However, placebo-control studies about SLIT
have been published since 1990 around the world and many of
them reported that SLIT was an effective treatment for pollen-
induced allergic airway diseases, and especially seasonal AR (5-
10). The effectiveness of SLIT for patients with house dust mites
AR has recently been revealed (2, 11). Based on others studies,
we anticipate the good long-term results of our series. 
Forty six percent of the patients were satisfied with receiving
SLIT and 12% were unsatisfied. Forty two percent of the patients
answered as fairly satisfied. When comparing the NTSSs before
and after SLIT for the unsatisfied patients, the NTSS was not
significantly improveder SLIT. Furthermore, although both the
satisfied and the fairly satisfied groups got better, the NTSSs
before and after SLIT vere higher in the latter group. Considering
the relationship between the satisfaction and the symptoms, the
degree of improvement of symptoms affected the patient satis-
faction. As this study included the patients who were treated with
SLIT for 6-13 months and a longer duration of SLIT induced bet-
ter results (12), it is thought that the proportion of the satisfied
group will increase with time. One study that was conducted in
Korea and that assessed the patient satisfaction for SCIT revealed
that 47.2%, 38.9%, and 13.9% of the patients receiving SCIT
felt satisfied, fairly satisfied and unsatisfied, respectively, and the
proportion of the satisfied patients was higher in the 3-yr imm-
unotherapy group than that in 1- or 2-yr immunotherapy group
(13). The results of that report were similar to ours and the short-
term satisfaction with SLIT was not different from that for SCIT.
SLIT induces much fewer systemic side effects and the major-
ity of adverse effects have been local reactions (4, 14). No sys-
temic allergic reactions were reported in the clinical trials of com-
mercial allergen extracts. Three case reports of anaphylaxis after
SLIT were published in the English medical literature and none
of these reactions occurred with using the commercially available
allergen. Two of these case reports described anaphylaxis that
was due to a mixture of multiple allergens and the third case was
due to latex (15-17). There have been no cases of mortality, and
SLIT is known to be safer than SCIT. In our series, 52% of the
92 patients complained of adverse effects. The most common
adverse effect was aggravation of the AR symptoms. Although
some patients complained of breathing discomfort or wheezing,
there was no case requiring other medical intervention or emer-
gency treatment due to adverse effects. Two patients reported
wheezing symptoms during the up-dosing phase. These two pa-
tients had a history of asthma and positive methacholine provo-
cation test results. Their wheezing symptoms were relieved spon-
taneously. Two patients complained of breathing discomfort and
they didn’t have asthma or bronchial hyper-responsiveness and
their symptoms resolved without medication. Aggravation of
asthmatic symptoms may be caused by allergen application; how-
ever, one case-control trial of SLIT reported that the incidence of
wheezing, as an adverse effect of SLT, was higher in the control
group than that for the patients who received SLIT (18). There-
fore, the asthmatic symptoms during SLIT were not only caused
by the adverse effect of allergen application, but they were also
caused by related factors such as neurosis or environmental effects.
The incidence of adverse effects was high during the up-dosing
phase in our study, which is similar to the results of other stud-
ies (4, 14), and these adverse effects subsided without specific
treatment when continuing SLIT. Although the adverse effects
subsided without emergency treatment, the incidence of adverse
effects in our study was higher than that of other studies. How-
ever, the difference of the incidences was not appreciable. While
the incidences were reported to be less than 10% in post-mar-
keting surveys (19, 20), one large meta-analytic study showed
that the incidence of adverse events in those patients receiving
active treatment was 39% compared with approximately 23%
in the placebo group (18). The results of that meta-analytic report
were similar to ours. Furthermore, we included the patients who
were sensitized to house dust mites, which cause perennial aller-
gic disease. Therefore, the symptomatic aggravation of allergic
rhinoconjunctivitis, which the participants reported as an adverse
effect, involved not only the true adverse effects, but also disease
aggravation that was due to environmental allergen. 
In Western countries, the drop out rate of SLIT was reported
to be 7-30% and the main reason for discontinuation was the
inability to take the study medication according to schedule or
the lack of efficacy (2, 21, 22). The drop-out rate of our series
was 31%, which was relative high when considering the short-
term follow-up results. The lack of efficacy and the discomfort
with taking medication regularly were the main reasons and half
of the drop-out patients discontinued in the first 3 months. Because
the inconvenient application of allergen was the main reason for
drop-out, the drop out rate could be lowered by developing a
more convenient application schedule such as a shortened up-
dosing phase, a reduced frequency of allergen application dur-
ing the maintenance therapy and a user-friendly allergen formu-
la. In another study that used a shortened up-dosing phase (10
days) and a convenient allergen formula, (SLITone
�, ALK-Abello,
Lainate, Italy), which contained 90 monodose containers and
counting drops of allergen solution wasn’t required, the drop out
rate was lower than ours (22). Moreover, it is necessary to edu-
cate the patients to understand SLIT properly because the timing
of discontinuance was too short to judge the efficacy of SLIT. 
In this study, we observed that subjective symptoms were im-
proved with short-term SLIT for house dust mites despite of only
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6-13 months of immunotherapy and 45.7% of the patients were
satisfied with SLIT. The adverse effects were mostly local reac-
tions and these subsided without other treatment. The incidence
of adverse effects was high in the up-dosing phase and this was
lowered after continuing immunotherapy. Therefore, we should
be alert for adverse effects during the up-dosing phase. The drop
out rate was 31%, which is relatively high compared to other
studies. Further long-term studies are required to evaluate if the
reduced allergic symptoms persist, which was observed during
short-term SLIT, and if the symptoms get better in the patients
who didn’t show symptom improvement with short-term SLIT.
Proper and prudent management of the patients is needed to
reduce the drop out rate. 
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